For one, iRGD administration is used to enhance transcytosis of silicasome-loaded irinotecan through the neuropilin-1 (NRP-1) pathway for the treatment of pancreatic ductal adenocarcinoma (PDAC). This evidence concerns the gene NRP1 and pancreatic ductal adenocarcinoma.